Raphaël Bourgade

Raphaël Bourgade

Pathology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
NRNoémie Rabilloud
Noémie Rabilloud
PAPierre Allaume
Pierre Allaume
OAOscar Acosta
Oscar Acosta
RCRenaud De Crevoisier
Renaud De Crevoisier
RBRaphaël Bourgade
Raphaël Bourgade
Solene-Florence Kammerer-JacquetSolene-Florence Kammerer-Jacquet
Solene-Florence Kammerer-Jacquet
Deep learning (DL), often called artificial intelligence (AI), has been increasingly used in Pathology thanks to the use of scanners to digitize slides which allow us to visualize them on monitors and process them with AI algorithms. Many articles have focused on DL applied to prostate cancer (PCa). This systematic review explains the DL applications and their performances for PCa in digital pathology. Article research was performed using PubMed and Embase to collect relevant articles. A Risk of Bias (RoB) was assessed with an adaptation of the QUADAS-2 tool. Out of the 77 included studies, eight focused on pre-processing tasks such as quality assessment or staining normalization. Most articles (n = 53) focused on diagnosis tasks like cancer detection or Gleason grading. Fifteen articles focused on prediction tasks, such as recurrence prediction or genomic correlations. Best performances were reached for cancer detection with an Area Under the Curve (AUC) up to 0.99 with algorithms already available for routine diagnosis. A few biases outlined by the RoB analysis are often found in these articles, such as the lack of external validation. This review was registered on PROSPERO under CRD42023418661.

12 August 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
RBRaphaël Bourgade
Raphaël Bourgade
NRNoémie Rabilloud
Noémie Rabilloud
TPTanguy Perennec
Tanguy Perennec
TPThierry Pécot
Thierry Pécot
CGCéline Garrec
Céline Garrec
DLDelphine Loussouarn
Delphine Loussouarn

Verified
Journal Article
Open access
PDF file
SFSamuel Frey
Samuel Frey
RBRaphaël Bourgade
Raphaël Bourgade
CMCédric Le May
Cédric Le May
MCMikael Croyal
Mikael Croyal
EBEdith BIGOT-CORBEL
Edith BIGOT-CORBEL
CBClaire Blanchard
Claire Blanchard
Background: The benefits of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism (PHPT) are controversial. This monocentric, observational, prospective study aimed to assess the effects of parathyroidectomy on glucose and lipid metabolism in classic or mild PHPT. Methods: Patients who underwent parathyroidectomy for classic (calcemia >2.85 mmol/L) or mild PHPT (calcemia ≤2.85 mmol/L) between 2016 and 2019 were included. A metabolic assessment was performed before and 1 year after parathyroidectomy. Patients with a history of diabetes were excluded. Results: Nineteen patients had classic and 120 had mild PHPT. Ninety-five percent were normocalcemic 6 months after surgery. Fasting plasma glucose and insulin levels decreased after parathyroidectomy in patients with mild PHPT (p < 0.001). HOMA-IR decreased after surgery in the overall population (p < 0.001), while plasma adiponectin concentrations increased in patients with both classic (p = 0.005) and mild PHPT (p < 0.001). Plasma triglyceride levels decreased significantly only in patients with classic PHPT (p = 0.021). Plasma PCSK9 levels decreased in patients with mild PHPT (p < 0.001). Conclusions: Parathyroidectomy for PHPT improves insulin resistance and decreases plasma triglyceride levels in classic PHPT and plasma PCSK9 levels in mild PHPT. Further studies are needed to better characterize the consequences of such metabolic risk factors’ improvements on cardiovascular events.

20 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DLDelphine Loussouarn
Delphine Loussouarn
OLOliver Lisa
Oliver Lisa
CSCeline Salaud
Celine Salaud
ESEdouard Samarut
Edouard Samarut
RBRaphaël Bourgade
Raphaël Bourgade
FVFrançois Vallette
François Vallette
Only a minority of patients with glioblastoma (GBM) respond to immunotherapy, and always only partially. There is a lack of knowledge on immune distribution in GBM and in its tumor microenvironment (TME). To address the question, we used paired primary and recurrent tumors from GBM patients to study the composition and the evolution of the immune landscape upon treatment. We studied the expression of a handful of immune markers (CD3, CD8, CD68, PD-L1 and PD-1) in GBM tissues in 15 paired primary and recurrent GBM. In five selected patients, we used Nanostring Digital Spatial Profiling (DSP) to obtain simultaneous assessments of multiple biomarkers both within the tumor and the microenvironment in paired primary and recurrent GBM. Our results suggest that the evolution of the immune landscape between paired primary and recurrent GBM tumors is highly heterogeneous. However, our study identifies B3-H7 and HLA-DR as potential targets in primary and recurrent GBM. Spatial profiling of immune markers from matched primary and recurrent GBM shows a nonlinear complex evolution during the progression of cancer. Nonetheless, our study demonstrated a global increase in macrophages, and revealed differential localization of some markers, such as B7-H3 and HLA-DR, between GBM and its TME.


15 July 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
RBRaphaël Bourgade
Raphaël Bourgade
MEMounia Elhannani
Mounia Elhannani
DLDelphine Loussouarn
Delphine Loussouarn
AGAlexis Guédon
Alexis Guédon
RPRenaud Péteri
Renaud Péteri
Charles LépineCharles Lépine
Charles Lépine